Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Surat
Clinical trial register · India

Clinical Trials in Surat, 2026

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1120 matching records held by the registry are in this view. Synced 08 Nov 2026, 03:16 UTC
1120
Studies in scope
all four open statuses
608
Recruiting now
open to new participants
218
Lead sponsors
across recruiting studies
Top sites
New Delhi 339 Mumbai 260 Hyderabad 233 Bangalore 199 Pune 186
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Novo Nordisk A/S14 Pfizer10 AstraZeneca8 Hoffmann-La Roche7 Janssen Research & Development, LLC6
Site location
New Delhi339 Mumbai260 Hyderabad233 Bangalore199 Pune186
All 274 locations
Target enrolment
to

Trials with a site in Surat

86 of 1120 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Not yet open
Novo Nordisk A/S
Phase 3
400
Surat, Vadodara, Hubbali, Kozhikode, Indore, Kohlapur, Kolhāpur, Mumbai
2027-01-07
Not yet open
AstraZeneca
Phase 3
330
Ansārinagar, Calicut, Kolkata, Ludhiana, Meerut, Surat
2027-01-04
Not yet open
Eli Lilly and Company
Phase 3
3,000
Belagavi, Guntur, Guwahati, Mumbai, Nagpur, Pune, Rishikesh, Surat
2026-12
Not yet open
Novo Nordisk A/S
Phase 3
8,500
Guntur, Vijayawada, Raipur, Ahmedabad, Surat, Vadodara, Faridabad, Gurugram
2026-10-26
Recruiting
Novo Nordisk A/S
Phase 3
1,778
Guntur, Raipur, Surat, Vadodara, Bangalore, Kochi, Kozhikode, Indore
2026-08-24
Recruiting
Novo Nordisk A/S
Phase 3
80
Guntur, Surat, Bangalore, New Delhi, Delhi, Kanpur, Kolkata, Kolhāpur
2026-08-04
Recruiting
Janssen Research & Development, LLC
Phase 3
644
Hubli, Hyderabad, Jaipur, Kochi, Mumbai (ex Bombay), Secunderabad, Surat
2026-05-23
Recruiting
Janssen Research & Development, LLC
Phase 3
460
Hubli, Hyderabad, Jaipur, Kochi, Mumbai (ex Bombay), Secunderabad, Surat
2026-05-22
Not yet open
Novo Nordisk A/S
Phase 3
1,000
Guntur, Surat, Vadodara, Bangalore, Bengaluru, Kochi, Indore, Mumbai
2026-05-20
Recruiting
Laboratoires Thea
Phase 2
120
Kolkata, Ahmedabad, Bangalore, Hyderabad, Jaipur, Patna, Pune, Surat
2026-03-24
Recruiting
Novo Nordisk A/S
Phase 3
460
Guntur, Surat, Bangalore, New Delhi, Delhi, Kanpur, Kolkata, Kolhāpur
2026-01-08
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
DrugsPF-08634404·Pembrolizumab
Pfizer
Phase 3
1,410
Surat, Vadodara, Gurugram, Bangalore, Belagavi, Kottayam, Nagpur, Nashik
2026-01-06
Recruiting
AstraZeneca
Phase 3
1,100
Bhubaneswar, Chennai, Delhi, Dhanvantari Nagar, Kolkata, Nagpur, Nashik, Surat
2025-12-29
Recruiting
AstraZeneca
Phase 3
1,100
Delhi, Hyderabad, Kolhāpur, Kolkata, Mumbai, Nashik, Surat
2025-12-04
By invitation
Celldex Therapeutics
Phase 3
1,370
Surat, Vadodara, Mysore, Nagpur, Nashik, Pune, Kanpur
2025-11-25
Active, closed
Qilu Pharmaceutical Co., Ltd.
Phase 3
146
Surat, Mangalore, Nashik, Thane, New Delhi, Bhubaneswar
2025-11-21
Recruiting
Daiichi Sankyo
Phase 3
686
Bangalore, Bhubaneswar, Howrah, Mangalore, Pune, Surat
2025-10-24
Active, closed
A Study of Mavacamten in Adults With Obstructive Hypertrophic Cardiomyopathy in India (ROVER)
NCT07004972Symptomatic Obstructive Hypertrophic Cardiomyopathy
DrugMavacamten
Bristol-Myers Squibb
Phase 4
50
Hyderabad, Ahmedabad, Surat, Gurgaon, Belagavi, Mangalore, Ernākulam, Kottayam
2025-09-04
Recruiting
Pfizer
Phase 3
400
Surat, Gurugram, Bengaluru, Mumbai, Nashik, Pune, Thane, Bhubaneswar
2025-08-05
Active, closed
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
NCT07037277HEPATITIS C VIRUS CHRONIC INFECTION, Hepatitis C, Chronic, Hepatitis C Virus Infection, Hepatitis C
DrugSofosbuvir-Velpatasvir
Atea Pharmaceuticals, Inc.
Phase 3
880
Hyderabad, Patna, Rajkot, Surat, Shimla, Belagavi, Kochi, Mumbai
2025-06-02
Recruiting
Pfizer
Phase 1
15
Surat, Mumbai
2025-05-13
Recruiting
Hoffmann-La Roche
Phase 3
425
Kurnool, Rajkot, Surat, Kochi, Nagpur (urban), New Delhi, Jaipur, Gachibowli
2025-05-12
Recruiting
Epygenix
Phase 3
260
Hyderabad, Ahmedabad, Surat, Calicut
2025-04-09
Recruiting
Hoffmann-La Roche
Phase 3
600
Kurnool, Rajkot, Surat, Kochi, Nagpur (urban), New Delhi, Jaipur, Gachibowli
2025-03-17
Recruiting
Novo Nordisk A/S
Phase 3
510
Guwahati, Raipur, Dohad, Surat, Vadodara, Mysuru, Kozhikode, Nagpur
2025-02-17
Active, closed
Janssen Research & Development, LLC
Phase 3
813
Ahmedabad, Bhubaneswar, Hubballi, Kolkata, Mysuru, New Delhi, Noida, Surat
2025-01-09
Active, closed
Pfizer
Phase 3
1,035
Surat, Gurugram, Bangalore, Mumbai, Nashik, Pune, Thane, New Delhi
2025-01-06
Active, closed
Hoffmann-La Roche
Phase 3
350
Surat, Nagpur (urban), Jaipur, Secunderabad
2024-12-11
Recruiting
GlaxoSmithKline
Phase 3
324
Ahmedabad, Bikaner, Kolkata, Mumbai, Surat
2024-11-13
Recruiting
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
NCT06528314NASH - Nonalcoholic Steatohepatitis, MASH - Metabolic Dysfunction-Associated Steatohepatitis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
2,150
Hyderabad, Surat, Vadodara, Mysore, Thiruvananthapuram, Mumbai, Nagpur, Pune
2024-10-04
Active, closed
Regeneron Pharmaceuticals
Phase 2
19
Ahmedabad, Surat, Kochi, Mumbai, New Delhi, Jaipur
2024-09-30
Recruiting
Pfizer
Phase 2
48
Surat, Bengaluru, Pune, Lucknow, Kolkata
2024-09-25
Active, closed
Hoffmann-La Roche
Phase 3
400
Surat, Jaipur
2024-09-17
Recruiting
Takeda
Phase 4
124
Vijayawada, Guwahati, Surat, Bangalore, Puducherry, Nashik, Navi Mumbai, Pune
2024-08-28
Recruiting
Jubilant Therapeutics India Limited
Phase 1
30
Surat, Bangalore, Mumbai, Nashik, Thane, New Delhi
2024-08-26
Recruiting
AstraZeneca
Phase 3
1,018
Delhi, Gurugram, Kolkata, Nashik, Surat, Thiruvananthapuram
2024-08-07
Active, closed
Celldex Therapeutics
Phase 3
976
Surat, Vadodara, Nagpur, Nashik, Pune, Jaipur, Kanpur, Ahmedabad
2024-07-19
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Guntur, Visakhapatnam, Raipur, Ahmedabad, Surat, Vadodara, Bengaluru, Mangaluru
2024-06-25
Recruiting
X4 Pharmaceuticals
Phase 3
176
Patna, Surat, Udaipur, Hyderabad
2024-06-06
Recruiting
Institute of Liver and Biliary Sciences, India
Observational
250
Guindy, Ahmedabad, Surat, Srinagar, Bengaluru, Mangalore, Kochi, Thiruvananthapuram
2024-05-02
Recruiting
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
NCT06318169Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
DrugPegozafermin
Hoffmann-La Roche
Phase 3
1,350
Guwahati, Allahābād, Kolkata, Bhubaneswar, Gujrāt, Nagpur, New Delhi, Surat
2024-03-13
Active, closed
nthalmic Pty Ltd
Not applicable
210
Surat, Hyderabad
2023-12-22
Recruiting
Akero Therapeutics, Inc
Phase 3
1,650
Surat, Vadodara, Mysore, Thiruvananthapuram, Dahegaon, Mumbai, Nagpur, Pune
2023-12-01
Active, closed
Akero Therapeutics, Inc
Phase 3
700
Surat, Vadodara, Thiruvananthapuram, Dahegaon, Mumbai, Nagpur, Pune, New Delhi
2023-11-10
Active, closed
Bristol-Myers Squibb
Phase 3
1,057
Ahmedabad, Surat, Belagavi, Bhopal, Nagpur, Pune, New Delhi, Mohali
2023-10-25
Recruiting
Aurigene Discovery Technologies Limited
Phase 1
40
Visakhapatnam, Chandigarh, Ahmedabad, Surat, Rohtak, Srinagar, Belagavi, Kochi
2023-10-19
Active, closed
Bristol-Myers Squibb
Phase 3
1,255
Ahmedabad, Surat, Belagavi, Bhopal, Nagpur, Pune, New Delhi, Mohali
2023-09-14
Recruiting
Hoffmann-La Roche
Phase 3
230
Ahmedabad, Surat, Gurugram, Mumbai, Nagpur, NEW Delhi Delhi, Kolkata
2023-09-08
Recruiting
Aurigene Discovery Technologies Limited
Phase 1
50
Vijayawada, Visakhapatnam, Chandigarh, Ahmedabad, Surat, Rohtak, Bangalore, Mysore
2023-09-05
Active, closed
Sanofi
Phase 2
999
Bengaluru, Bikaner, Kochi, Kolkata, Mangaluru, Nashik, Surat
2023-04-03
Active, closed
Novo Nordisk A/S
Phase 3
7,101
Guntur, Hyderabad, Vijayawada, Guwahati, Raipur, Ahmedabad, Surat, Vadodara
2023-03-01
Active, closed
A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A
NCT05685238Haemophilia A, Haemophilia A With Inhibitors
Novo Nordisk A/S
Phase 3
451
Surat, Mumbai, Pune, Ludhiana, Jaipur, Ranipet, Noida
2023-02-13
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Hyderabad, Secunderabad, Ahmedabad, Rajkot, Surat, Vadodara, Gurgaon, Bangalore
2023-01-16
Active, closed
Bristol-Myers Squibb
Phase 3
516
Vizianagaram, Ahmedabad, Surat, Gurugram, Bengaluru, Hyderabad
2023-01-12
By invitation
Tolmar Inc.
Phase 3
250
Surat, Bangalore, Bengaluru, Mysore, Nagpur, Pune, Erode, Varanasi
2022-12-28
Recruiting
Pfizer
Phase 3
100
Surat, Mumbai, Kolkata
2022-12-09
Active, closed
Novo Nordisk A/S
Phase 3
3,400
Surat, Belagavi, Kozhikode, Mumbai, Nagpur, Pune, Delhi, Chandigarh
2022-11-01
Recruiting
Pfizer
Phase 2/3
389
Raipur, Surat, Vadodara, Nashik, New Delhi, Bhubaneswar
2022-09-22
Active, closed
Janssen Research & Development, LLC
Phase 2
577
Bangalore, Bhubaneswar, Jaipur, New Delhi, Secunderabad, Surat
2022-09-19
Active, closed
AstraZeneca
Phase 3
594
Jaipur, Pune, Surat
2022-09-15
Active, closed
Janssen Research & Development, LLC
Phase 3
418
Gurugram, Hyderabad, Manipal, Mumbai, Surat
2022-09-13
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
529
Surat, Belagavi, Hubli, Pune, Bangalore, Chennai, Secunderabad, Sevilla
2022-06-30
Active, closed
Novo Nordisk A/S
Phase 3
153
Guwahati, Surat, Kolhāpur, Mumbai, Pune, Cuttack, Jaipur, Noida
2022-03-24
Active, closed
GlaxoSmithKline
Phase 2
366
Belagavi, Coimbatore, Hyderabad, Kanchan Bagh Hyderabad, Mumbai, New Delhi, Pune, Surat
2021-12-14
Active, closed
Regeneron Pharmaceuticals
Phase 3
288
Guntur, Surat, Panjagutta, Udupi, Kochi, Pune, Parel, New Delhi
2021-12-14
Recruiting
Pfizer
Phase 3
245
Surat, Mumbai, Pune, Kolkata
2021-11-17
Active, closed
AstraZeneca
Phase 3
927
Gūrgaon, Howrah, Nagpur, Nashik, New Delhi, Raipur, Rishikesh, Surat
2021-10-25
Active, closed
AstraZeneca
Phase 3
732
Gūrgaon, Howrah, Hyderabad, Jaipur, Kolkata, Nashik, Surat, Visakhapatnam
2021-10-18
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Vijayawada, Patna, Ahmedabad, Surat, Vadodara, Belagavi, Amravati, Kolhāpur
2021-08-27
Active, closed
Tolmar Inc.
Phase 3
250
Vijayawada, Visakhapatnam, Ahmedabad, Surat, Bengaluru, Mysore, Nagpur, Nashik
2021-07-01
Active, closed
Pfizer
Phase 3
599
Surat, Gurugram, Mumbai, Pune, New Delhi, Meerut, Kolkata
2021-05-12
Active, closed
Geron Corporation
Phase 3
327
Surat, Bangalore, Bengaluru, New Delhi, Gūrgaon, Bhubaneswar, Kolkata, Pune
2021-04-12
Active, closed
Novo Nordisk A/S
Phase 3
1,205
Secunderabad, Surat, Gurgaon, Mangalore, Mumbai, Nagpur, Delhi, Ghitorni
2021-04-01
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Surat, Bangalore, Mumbai, Nashik, New Delhi, Hyderabad
2020-12-22
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
DrugInebilizumab
Amgen
Phase 3
238
Nagpur, Hyderabad, Bangalore, Lucknow, Manipal, Nashik, Pune, Surat
2020-10-15
Recruiting
Epygenix
Phase 3
150
Hyderabad, Surat, Belagavi, Bengaluru, Kochi, Pune, Mumbai, Nagpur
2020-09-15
Active, closed
AstraZeneca
Phase 3
866
Bengaluru, Calicut, Kolkata, Marg Jaipur, New Delhi, Surat, Thiruvananthapuram
2020-07-24
Active, closed
Sun Pharmaceutical Industries Limited
Phase 3
296
Surat, Bangalore, Belagavi, Hubli, Pune, Hyderabad, Lucknow, Kochi
2020-07-01
Active, closed
Eli Lilly and Company
Phase 3
996
Chandigarh, Surat, Pune, New Delhi, Ludhiana, Jaipur, Chennai
2020-06-22
Active, closed
Sun Pharmaceutical Industries Limited
Phase 2/3
135
Ahmedabad, Lucknow, Surat
2020-01-15
Active, closed
Pfizer
Phase 3
896
Surat, Gurgaon, Nagpur, Pune, Jaipur, Kanpur
2019-09-05
Active, closed
Novo Nordisk A/S
Phase 3
1,500
Guntur, Surat, Bangalore, Kochi, Thiruvananthapuram, Thiruvnanthapuram, Mumbai, Nagpur
2019-05-08
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Jaipur, New Delhi, Noida, Rajkot, Surat
2018-04-13
Active, closed
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
NCT03165734Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
DrugPacritinib
Swedish Orphan Biovitrum
Phase 3
407
Guwahati, Chandigarh, Surat, Gurgaon, Pune, Jaipur, Madurai, Hyderabad
2017-06-26
Active, closed
Gilead Sciences
Phase 2
150
Kolkata, Lucknow, Mumbai, Nagpur, New Delhi, Surat, Varanasi
2016-11
Active, closed
Gilead Sciences
Phase 3
90
Surat, Gurgaon, Nagpur, Jaipur, Lucknow, Bangalore
2012-12-06
Rows per page Showing 1–86 of 86
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 8 November 2026. https://priyalifescience.com/clinical-trials-india/city/surat

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in India and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,120 studies in total at the last sync on 08 Nov 2026, 03:16 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 86 of those studies with a site in Surat.

How many clinical trials are recruiting in Surat?

34 of the 86 studies on this page are recruiting new participants as of the 08 Nov 2026, 03:16 UTC sync. A further 5 have not yet opened recruitment, 45 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Surat), 86 studies
PhaseStudiesRecruitingShare
Phase 3672477.9%
Phase 2728.1%
Phase 1444.7%
Phase 2/3313.5%
Phase 4323.5%
Not applicable101.2%
Observational111.2%

Most active sponsors

Lead sponsors with the most studies (Surat)
Lead sponsorStudiesRecruiting
Novo Nordisk A/S144
Pfizer107
AstraZeneca83
Hoffmann-La Roche74
Janssen Research & Development, LLC62
Bristol-Myers Squibb40
Akero Therapeutics, Inc32
Sun Pharmaceutical Industries Limited30
Aurigene Discovery Technologies Limited22
Celldex Therapeutics20
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.